Experimental study of cardiac lymph dynamics and edema formation in ischemia/reperfusion injury--with reference to the effect of hyaluronidase.
This study is designed to evaluate the effect of hyaluronidase on the canine myocardial edema derived from ischemia/reperfusion injury. The mongrel dog's heart received 90 minutes of ischemia under cardiopulmonary bypass consisting of 30 minutes of normothermia alone and 60 minutes of hypothermia with cardioplegic arrest. Reperfusion for 60 minutes was added thereafter. Two kinds of cardioplegic solution, 4 degrees C St. Thomas' Hospital solution with or without 3000 units/L of hyaluronidase, were prepared. The solution was given antegradely every 30 minutes during cardioplegic arrest. Cardiac lymph was collected continuously from the afferent duct of the cardiac lymph node by cannulation. Hyaluronidase in the cardioplegic solution increased cardiac lymph volume significantly and improved postischemic recovery of cardiac function. A high level of adenosine triphosphate was maintained at that time. The myocardial water content at the end of reperfusion revealed a minimum increase with hyaluronidase use. Active drainage of cardiac lymph by hyaluronidase alleviates the myocardial edema formation, thereby preserving cardiac function.
Yotsumoto
G
G
Second Department of Surgery, Kagoshima University, Faculty of Medicine, Sakuragaoka, Japan.
Moriyama
Y
Y
Yamaoka
A
A
Taira
A
A
D000255:Adenosine Triphosphate / Q000032:analysis / Q000378:metabolism; D000818:Animals; D001639:Bicarbonates / Q000008:administration & dosage / Q000627:therapeutic use; D001831:Body Temperature; D001834:Body Water / Q000737:chemistry / Q000378:metabolism; D002122:Calcium Chloride / Q000008:administration & dosage / Q000627:therapeutic use; D002314:Cardioplegic Solutions / Q000008:administration & dosage / Q000627:therapeutic use; D002315:Cardiopulmonary Bypass / Q000379:methods; D003971:Diastole; D004285:Dogs; D004489:Edema, Cardiac / Q000209:etiology* / Q000378:metabolism / Q000517:prevention & control; D006321:Heart / Q000187:drug effects / Q000503:physiopathology; D006324:Heart Arrest, Induced; D006821:Hyaluronoglucosaminidase / Q000008:administration & dosage / Q000627:therapeutic use*; D007036:Hypothermia, Induced; D007773:Lactates / Q000032:analysis / Q000378:metabolism; D008196:Lymph / Q000737:chemistry / Q000187:drug effects* / Q000378:metabolism; D008198:Lymph Nodes / Q000378:metabolism; D008208:Lymphatic System / Q000378:metabolism; D008274:Magnesium / Q000008:administration & dosage / Q000627:therapeutic use; D017202:Myocardial Ischemia / Q000150:complications* / Q000378:metabolism; D015425:Myocardial Reperfusion; D015428:Myocardial Reperfusion Injury / Q000150:complications* / Q000378:metabolism; D009206:Myocardium / Q000737:chemistry / Q000378:metabolism; D011189:Potassium Chloride / Q000008:administration & dosage / Q000627:therapeutic use; D012965:Sodium Chloride / Q000008:administration & dosage / Q000627:therapeutic use; D013997:Time Factors; D016277:Ventricular Function, Left / Q000187:drug effects; D017725:Ventricular Pressure / Q000187:drug effects
D001639:Bicarbonates; D002314:Cardioplegic Solutions; D007773:Lactates; C041711:St. Thomas' Hospital cardioplegic solution; D012965:Sodium Chloride; D011189:Potassium Chloride; D000255:Adenosine Triphosphate; D006821:Hyaluronoglucosaminidase; D008274:Magnesium; D002122:Calcium Chloride